2022 PTCTC Meeting Schedule

James LaBelle, MD PhD

---

8:15–9:15 am

Clonal Hematopoiesis and How Genetics Can Affect Transplant Donors, Recipients, and Post-Transplant Evaluation

Esther Obeng, MD PhD

CHIP in Healthy Adult Donors and Pediatric Remission/Pre-Transplant Samples
Esther Obeng, MD PhD

Oncologic Complications of Gene Therapy for Nonmalignant Disorders
Christine Duncan, MD

Non-Myeloablative Conditioning and Hematologic Malignancies
Courtney Fitzhugh, MD

---

9:15–10:15 am

Pediatric Chronic Graft-Versus-Host-Disease: Case-Based Approaches to Diagnosis and New Therapies

Geoff Cuvelier, MD, FRCPC

Aspects of Clinical cGVHD in Children
Geoff Cuvelier, MD, FRCPC

Therapy of cGVHD in Children
Jennifer Whangbo, MD, PhD

---

10:15–10:30 am

Break

---

10:30–11:30 am

Re-Investigation of Immunological Barriers to Engraftment Post-Transplant

Mike Verneris, MD

Antibody Conditioning for Hematopoietic Cell Transplantation: Bench to Bedside
Judith Shizuru, MD

JAK inhibitors facilitate hematopoietic cell engraftment following allogeneic BMT
Laura McLaughlin, MD

---

11:30 am–12:30 pm

Post-Transplant Disease-Specific Therapies for Leukemia-When, What, and for How Long?

James LaBelle, MD PhD

TKIs for Post-Cellular Therapy Maintenance in Ph+ ALL
Adam Duvall, MD

Maintenance Approaches for Myeloid disease- Who, What and When?
Jessica Pollard, MD

Immunotherapeutic Approaches for Post-Transplant Relapse
Corrine Summer, MD

---

1–2 pm

Non-CME Lunch Symposia

Rising to the Challenge of Identifying and Treating VOD/SOS Post HSCT

Speakers:

• Ken Cooke, MD. Johns Hopkins
• Mitch Cairo, MD. New York Medical College

---

2:30–3:30 pm

Madan Kumar, DO

Post-Transplant Revaccination in the Time of COVID and Markers of a Functional Immune System

Influenza Vaccine Response in HCT Recipients
Natasha Halasa, MD

Immune Reconstitution and Optimal Timing of Vaccine Administration
Jeffrey Auletta, MD

Prevention of SARS-CoV-2 after HSCT
Madan Kumar, DO

---

3:30–4:45 pm

Abstract Presentations

Moderators: James LaBelle, MD; Sung Won Choi, MD MS

Obesity increases endothelial injury following hematopoietic stem cell transplant
Jane Koo, MD

Treating Children, Adolescents, and Young Adults (CAYA) with Refractory Viral Infections in Primary Immunodeficiencies (PID), or Post Solid Organ Transplant (SOT) or Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) with Virus Specific T- Lymphocytes (vCTLs)
Julie-An Talano, MD

The Impact of Race, Ethnicity, and Obesity on CAR T-cell Therapy Outcomes in Children and Young Adults with B-cell Acute Lymphoblastic Leukemia (B-ALL)
Aiman Faruqi

Hospital Mandated Restrictions During the COVID-19 Pandemic Alter Hospital Acquired Viral Respiratory Infections During Hematopoietic Stem Cell Transplantation: A Single Center Experience
Perry Morocco, MD

Targeting Ewing sarcoma (ES), Osteosarcoma (OS) and Neuroblastoma (NB) with Anti-MCAM Chimeric Antigen Receptor (CAR) Modified Natural Killer (NK) Cells
Wen Luo, MD

---

4:45–5:00 pm

Break

---

5:00–6:00 pm

How to Survive AND Be Happy in Academia: Laying the Groundwork for a 1, 3, 5, and 8-10 Year Plan

Discussants:

• Leslie Kean, MD PhD
• Mike Verneris, MD
• Mitch Cairo, MD
• Paul Szabolcs, MD
• Sung Won Choi, MD MS

---

PTCTC Advanced Practice Leadership Roles

Discussants:

• Chelsea Balian, MSN RN CNS CPNP
• Karen Wolownik, MSN RN CPNP CPHON

---

6:00–6:15 pm

Closing Address

James LaBelle, MD PhD
Sung Won Choi, MD MS

---

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Society of Pediatric Hematology/Oncology (ASPHO) and the Pediatric Transplantation and Cellular Therapy Consortium (PTCTC). The American Society of Pediatric Hematology/Oncology is accredited by the ACCME to provide continuing medical education for physicians.

The American Society of Pediatric Hematology/Oncology designates this live activity for a maximum of 7.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure

In accordance with the Accreditation Council for Continuing Medical Education's (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, ASPHO requires all planners, faculty (presenters and moderators), reviewers, teachers, authors, and any others involved in the development of CME content to disclose all financial relationships they have with ineligible companies in the last 24 months. Ineligible companies are defined as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. ASPHO also requires disclosure of the intent to discuss unlabeled or investigational use(s) of a commercial product or investigational use of a product not yet approved for this purpose. The ASPHO Accreditation Subcommittee reviews all financial relationships as submitted in the disclosure form by planners and presenters and resolves such conflicts to ensure the content of the activity is aligned with the interests of the public.

Disclaimer

The materials presented in this activity represent the opinions of the speakers and not necessarily the views of ASPHO or PTCTC.